| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| EXELExelixis, Inc. | 11.81B | 44.06 | 15.85 | 6.98% | 29.63% | 31.37% | 7.49% | 0.08 |
| INCYIncyte Corporation | 20.1B | 101.27 | 15.80 | 21.22% | 25.03% | 24.9% | 6.74% | 0.01 |
| GMABGenmab A/S | 18.13B | 29.44 | 15.36 | 30.67% | 46.8% | 114.25% | 6.6% | 0.03 |
| SNDXSyndax Pharmaceuticals, Inc. | 1.89B | 21.71 | -5.82 | -279.31% | -269.93% | 1.20 | ||
| RCUSArcus Biosciences, Inc. | 2.55B | 20.37 | -6.19 | -4.26% | -142.91% | -55.94% | 0.16 | |
| RLAYRelay Therapeutics, Inc. | 1.78B | 10.26 | -6.37 | 53.44% | -18.01% | -48.76% | 0.06 | |
| STROSutro Biopharma, Inc. | 1.74B | 20.47 | -6.92 | -59.64% | -205.18% | -234.19% | 4.57 | |
| OLMAOlema Pharmaceuticals, Inc. | 1.66B | 24.20 | -11 | -48.77% | 0.00 |
Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 829K | 2.64M | 3.73M | 0 |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | -829K | -2.64M | -3.73M | 0 |
| Gross Margin % | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | -218.58% | -41.31% | 100% |
| Operating Expenses | 13.29M | 109.25M | 124.05M | 244.81M | 137.79M | 179.59M |
| OpEx % of Revenue | - | - | - | - | - | - |
| Selling, General & Admin | 3.68M | 7.96M | 22.62M | 32.99M | 37.7M | 41.73M |
| SG&A % of Revenue | - | - | - | - | - | - |
| Research & Development | 9.62M | 101.3M | 73.92M | 112.46M | 103.82M | 115.36M |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 27.52M | 99.36M | -3.73M | 22.5M |
| Operating Income | -13.29M | -109.25M | -124.88M | -247.45M | -141.53M | -179.59M |
| Operating Margin % | - | - | - | - | - | - |
| Operating Income Growth % | - | -721.81% | -14.31% | -98.15% | 42.81% | -26.89% |
| EBITDA | -12.98M | -108.71M | -124.05M | -244.81M | -137.79M | -175.78M |
| EBITDA Margin % | - | - | - | - | - | - |
| EBITDA Growth % | - | -737.28% | -14.11% | -97.34% | 43.71% | -27.57% |
| D&A (Non-Cash Add-back) | 310K | 540K | 829K | 2.64M | 3.73M | 3.81M |
| EBIT | -13.29M | -37.51M | -122.76M | -242.81M | -125.04M | -157.09M |
| Net Interest Income | 1.3M | 336K | 190K | -196.46M | 16.71M | 20.09M |
| Interest Income | 1.3M | 336K | 190K | 4.9M | 16.71M | 20.09M |
| Interest Expense | 0 | 0 | 0 | 201.36M | 0 | 0 |
| Other Income/Expense | 1.25M | 7.59M | 2.12M | 4.64M | 16.48M | 17.94M |
| Pretax Income | -12.04M | -101.66M | -122.76M | -242.81M | -125.04M | -161.65M |
| Pretax Margin % | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 100% | 100% | 100% | 100% | 100% | 100% |
| Net Income | -12.04M | -101.66M | -122.76M | -242.81M | -125.04M | -161.65M |
| Net Margin % | - | - | - | - | - | - |
| Net Income Growth % | - | -744.35% | -20.76% | -97.78% | 48.5% | -29.28% |
| Net Income (Continuing) | -12.04M | -101.66M | -122.76M | -242.81M | -125.04M | -161.65M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.10 | -0.85 | -1.03 | -1.99 | -0.83 | -0.69 |
| EPS Growth % | - | -750% | -21.18% | -93.2% | 58.29% | 16.87% |
| EPS (Basic) | -0.10 | -0.85 | -1.03 | -1.99 | -0.83 | -0.69 |
| Diluted Shares Outstanding | 118.96M | 118.96M | 119.1M | 122.02M | 150.18M | 233.82M |
| Basic Shares Outstanding | 118.96M | 118.96M | 119.1M | 122.02M | 150.18M | 233.82M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 51.12M | 119.99M | 420.02M | 444.5M | 320.68M | 308.79M |
| Cash & Short-Term Investments | 50.37M | 118.7M | 414.48M | 435.62M | 312.35M | 298.31M |
| Cash Only | 29.58M | 65.38M | 360.49M | 284.22M | 93.08M | 67.74M |
| Short-Term Investments | 20.79M | 53.33M | 53.99M | 151.4M | 219.28M | 230.57M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 2.3M |
| Days Sales Outstanding | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 0 | 1.29M | 100K | 748K | 1.1M | 8.18M |
| Total Non-Current Assets | 4.39M | 4.83M | 81.4M | 70.41M | 74.62M | 193.73M |
| Property, Plant & Equipment | 4.33M | 4.07M | 33.31M | 65.23M | 60.19M | 48.54M |
| Fixed Asset Turnover | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 312K | 44.77M | 2M | 10.05M | 142.16M |
| Other Non-Current Assets | 56K | 451K | 3.32M | 3.18M | 4.38M | 3.03M |
| Total Assets | 55.51M | 124.83M | 501.42M | 514.91M | 395.3M | 502.53M |
| Asset Turnover | - | - | - | - | - | - |
| Asset Growth % | - | 124.86% | 301.69% | 2.69% | -23.23% | 27.13% |
| Total Current Liabilities | 2.75M | 13.68M | 26.22M | 48.69M | 26.16M | 31.39M |
| Accounts Payable | 1.38M | 878K | 4.68M | 23.05M | 2M | 468K |
| Days Payables Outstanding | - | - | 2.06K | 3.19K | 195.61 | - |
| Short-Term Debt | 0 | 877K | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 447K | 9.51M | 4.16M | 2.33M | 10.78M | 0 |
| Current Ratio | 18.59x | 8.77x | 16.02x | 9.13x | 12.26x | 9.84x |
| Quick Ratio | 18.59x | 8.77x | 16.02x | 9.13x | 12.26x | 9.84x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 66.37M | 3.72M | 18.66M | 54.37M | 52.45M | 47.63M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 2.96M | 2.11M | 18.51M | 53.79M | 51.89M | 47.27M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 63.4M | 1.61M | 158K | 573K | 566K | 362K |
| Total Liabilities | 69.12M | 17.4M | 44.89M | 103.06M | 78.61M | 79.03M |
| Total Debt | 3.69M | 2.99M | 18.79M | 55.1M | 55.86M | 51.89M |
| Net Debt | -25.89M | -62.39M | -341.7M | -229.12M | -37.22M | -15.85M |
| Debt / Equity | - | 0.03x | 0.04x | 0.13x | 0.18x | 0.12x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | - | - | - | -1.23x | - | - |
| Total Equity | -13.6M | 107.42M | 456.53M | 411.85M | 316.69M | 423.5M |
| Equity Growth % | - | 889.63% | 324.99% | -9.79% | -23.11% | 33.73% |
| Book Value per Share | -0.11 | 0.90 | 3.83 | 3.38 | 2.11 | 1.81 |
| Total Shareholders' Equity | -13.6M | 107.42M | 456.53M | 411.85M | 316.69M | 423.5M |
| Common Stock | 3K | 3K | 12K | 15K | 15K | 28K |
| Retained Earnings | -13.74M | -115.4M | -238.17M | -480.97M | -606.01M | -767.66M |
| Treasury Stock | -124K | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 11K | 2K | -162K | -1.04M | 77K | 405K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -10.38M | -32.69M | -79.6M | -103.26M | -101.22M | -109.42M |
| Operating CF Margin % | - | - | - | - | - | - |
| Operating CF Growth % | - | -214.95% | -143.53% | -29.73% | 1.98% | -8.1% |
| Net Income | -12.04M | -101.66M | -122.76M | -242.81M | -125.04M | -161.65M |
| Depreciation & Amortization | 310K | 540K | 829K | 2.64M | 3.73M | 3.81M |
| Stock-Based Compensation | 122K | 797K | 8.33M | 20.11M | 26.23M | 26.97M |
| Deferred Taxes | 0 | 0 | -1.51M | 0 | 0 | 0 |
| Other Non-Cash Items | -483K | 64.35M | 27.81M | 101.01M | -6.95M | 19.72M |
| Working Capital Changes | 1.71M | 3.29M | 7.71M | 15.79M | 813K | 1.74M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.17M | -380K | 1.34M | 676K | -886K | -1.53M |
| Cash from Investing | -20.89M | -71.2M | -64.59M | -71.08M | -91.22M | -156.62M |
| Capital Expenditures | -597K | -947K | -18.89M | -16.55M | -1.77M | -60K |
| CapEx % of Revenue | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 7.68M | 4M | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | -37.74M | -7.68M | -4M | -20M | -22.5M |
| Cash from Financing | 16.86M | 139.99M | 439.4M | 98.08M | 1.29M | 240.7M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 3.02M | 3M | 2.82M | 0 | 1.64M |
| Net Change in Cash | -14.4M | 36.1M | 295.21M | -76.27M | -191.14M | -25.34M |
| Free Cash Flow | -10.97M | -71.38M | -98.48M | -119.81M | -102.99M | -131.98M |
| FCF Margin % | - | - | - | - | - | - |
| FCF Growth % | - | -550.37% | -37.98% | -21.66% | 14.04% | -28.14% |
| FCF per Share | -0.09 | -0.60 | -0.83 | -0.98 | -0.69 | -0.56 |
| FCF Conversion (FCF/Net Income) | 0.86x | 0.32x | 0.65x | 0.43x | 0.81x | 0.68x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 13K | 69K | 0 | 0 | 0 | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -216.72% | -43.54% | -55.92% | -34.33% | -43.68% |
| Return on Invested Capital (ROIC) | - | -2961.83% | -117.18% | -124.74% | -45.93% | -39.2% |
| Debt / Equity | - | 0.03x | 0.04x | 0.13x | 0.18x | 0.12x |
| Interest Coverage | - | - | - | -1.23x | - | - |
| FCF Conversion | 0.86x | 0.32x | 0.65x | 0.43x | 0.81x | 0.68x |
Explore detailed financial history, valuation models, and returns analysis
DCF models, peer multiples & analyst estimates
Historical returns with dividends reinvested
Yield, growth, payout safety & DRIP calculator
EPS trends, net income & profitability analysis
Long-term charts & historical price data
Sales growth patterns & revenue breakdown
30 years of valuation, profitability & efficiency metrics